[{"address1": "188 East Blaine Street", "address2": "Suite 200", "city": "Seattle", "state": "WA", "zip": "98102", "country": "United States", "phone": "206 788 4545", "website": "https://www.alpineimmunesciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.", "fullTimeEmployees": 142, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mitchell H. Gold M.D.", "age": 55, "title": "Executive Chairman & CEO", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 1023300, "exercisedValue": 0, "unexercisedValue": 16418501}, {"maxAge": 1, "name": "Dr. Stanford  Peng M.D., Ph.D.", "age": 52, "title": "President and Head of Research & Development", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 940100, "exercisedValue": 0, "unexercisedValue": 11788008}, {"maxAge": 1, "name": "Mr. Paul  Rickey", "age": 44, "title": "Senior VP, CFO, Treasurer & Secretary", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 691100, "exercisedValue": 0, "unexercisedValue": 2395806}, {"maxAge": 1, "name": "Mr. Ulrich Martin Fuhs", "age": 55, "title": "VP of Finance & Chief Accounting Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. M. Christina Yi", "age": 47, "title": "Chief Technology Officer", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Greenblatt", "title": "Director of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Remy  Durand Ph.D.", "age": 37, "title": "Chief Business Officer", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew Seth Sandler M.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 64.97, "open": 64.98, "dayLow": 64.97, "dayHigh": 64.97, "regularMarketPreviousClose": 64.97, "regularMarketOpen": 64.98, "regularMarketDayLow": 64.97, "regularMarketDayHigh": 64.97, "beta": 0.969, "forwardPE": -32.485, "volume": 4288333, "regularMarketVolume": 4288333, "averageVolume": 2553881, "averageVolume10days": 1656670, "averageDailyVolume10Day": 1656670, "marketCap": 4456779776, "fiftyTwoWeekLow": 8.33, "fiftyTwoWeekHigh": 65.0, "priceToSalesTrailing12Months": 78.85175, "fiftyDayAverage": 53.1542, "twoHundredDayAverage": 26.835125, "currency": "USD", "enterpriseValue": 4160775424, "profitMargins": -0.65172, "floatShares": 47881760, "sharesOutstanding": 68597504, "sharesShort": 3887995, "sharesShortPriorMonth": 5284601, "sharesShortPreviousMonthDate": 1711584000, "dateShortInterest": 1714435200, "sharesPercentSharesOut": 0.059299998, "heldPercentInsiders": 0.0465, "heldPercentInstitutions": 0.99469, "shortRatio": 0.96, "shortPercentOfFloat": 0.08270001, "impliedSharesOutstanding": 68597504, "bookValue": 5.075, "priceToBook": 12.801971, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -36836000, "trailingEps": -0.64, "forwardEps": -2.0, "lastSplitFactor": "1:4", "lastSplitDate": 1500940800, "enterpriseToRevenue": 73.615, "enterpriseToEbitda": -81.952, "52WeekChange": 5.060634, "SandP52WeekChange": 0.24688339, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ALPN", "underlyingSymbol": "ALPN", "shortName": "Alpine Immune Sciences, Inc.", "longName": "Alpine Immune Sciences, Inc.", "firstTradeDateEpochUtc": 1434547800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e994e1f0-358a-395f-b1e2-8dc3a2a1a651", "messageBoardId": "finmb_283828497", "gmtOffSetMilliseconds": -14400000, "currentPrice": 64.97, "targetHighPrice": 65.0, "targetLowPrice": 44.0, "targetMeanPrice": 62.0, "targetMedianPrice": 65.0, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 305660992, "totalCashPerShare": 4.456, "ebitda": -50771000, "totalDebt": 9655000, "quickRatio": 9.498, "currentRatio": 9.562, "totalRevenue": 56521000, "debtToEquity": 2.902, "revenuePerShare": 1.044, "returnOnAssets": -0.10097, "returnOnEquity": -0.14669, "freeCashflow": -41412752, "operatingCashflow": -80550000, "revenueGrowth": -0.251, "grossMargins": -0.48228002, "ebitdaMargins": -0.89827, "operatingMargins": -3.22753, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-06"}]